Laëtitia Bénard
Partner – Paris
Tel +33140065033
laetitia.benard@allenovery.com
Laëtitia leads the Paris IP practice and is co-head of Allen & Overy’s Life Sciences Group worldwide. She has specific expertise in the pharmaceutical sector, where she advises client on various regulatory and contractual matters such as price regulation, advertisement for medicines, transfers of technology and anti-bribery rules.
Laëtitia was recognized by Best Lawyers as the leading Biotechnology practitioner in France. Clients observe that “she has developed profound expertise in the pharmaceutical and biotech areas, both in regulatory and contentious areas.”
Posts by: Laëtitia Bénard
- France clarifies situations in which physicians and pharmacists can exclude generic substitution
- France: Innovative medicines marketed too slowly
- Rewarding innovation: pharmaceutical incentives as a crucial instrument to foster public health
- French IPO allows extension of the duration of SPCs on the basis of the MA notification date
- EU Competitiveness Council to review Current Status of the Unitary Patent and Unified Patent Court
- Proposals for reform of EU Paediatric Regulation postponed - EC to take another look at orphan incentives for paediatric medicines
- European Commission opens public consultation on SPCs and patent research exemptions
- EPO reverses its position on the patentability of products obtained by essentially biological processes
- ANSM publishes results of French pilot project on new EU clinical trials procedures
- French Parliament approves expanding substitution of biosimilars
- French Parliament debates on expanding substitution of biosimilars
- ANSM opens public consultation with respect to its draft recommendations on medicinal product names
- ANSM issues measures regarding first-in-human trials in wake of French trial tragedy